BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
BIOCYTOGEN-B: ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THESIX MONTHS ENDED JUNE 30, 2024
BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
BIOCYTOGEN-B: VOLUNTARY ANNOUNCEMENTENTERS INTO OPTION AND LICENSE AGREEMENT WITH IDEAYAFOR POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOADBISPECIFIC ADC PROGRAM
BIOCYTOGEN-B: VOLUNTARY ANNOUNCEMENTENTERS INTO MULTI-TARGET ANTIBODY AGREEMENT WITH SOTIO
BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
BIOCYTOGEN-B: VOLUNTARY ANNOUNCEMENT Biocytogen Secures U.S. Patent for RenLiteCommon Light Chain Mouse Platform
BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
BIOCYTOGEN-B: FORM OF PROXY FOR THE USE AT THE 2023 ANNUAL GENERAL MEETING
BIOCYTOGEN-B: (1)2023 ANNUAL REPORT... (2)WORK REPORT OF BOARD (3)WORK REPORT OF SUPERVISORY COMMITTEE (4)FINAL ACCOUNTS REPORT (5)PROPOSED RE-APPOINTMENT OF AUDITOR (6)PROPOSED REMUNERATION OF DIRECTORS (7)PROPOSED REMUNERATION OF SUPERVISORS (8)PROPOSED PROFIT DISTRIB
BIOCYTOGEN-B: VOLUNTARY ANNOUNCEMENT (1) UNUSUAL PRICE MOVEMENT; AND (2) SHARE PURCHASE BY TRUSTEE PURSUANT TO SHARE AWARD SCHEME
BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
BIOCYTOGEN-B: ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FORTHE YEAR ENDED DECEMBER 31, 2023
BIOCYTOGEN-B: VOLUNTARY ANNOUNCEMENTBIOCYTOGEN AND GILEAD ENTER INTO A MULTI-TARGETANTIBODY COLLABORATION AGREEMENT
BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
BIOCYTOGEN-B: VOLUNTARY ANNOUNCEMENTBIOCYTOGEN ENTERED INTO A BISPECIFIC ANTIBODYDRUG CONJUGATE AGREEMENT WITH RADIANCE BIOPHARMA
BIOCYTOGEN-B: Overseas Regulatory Announcement
BIOCYTOGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
No Data